United-Guardian (UG) Q4 2024 earnings summary

Executive summary

• Net sales increased by 12% year-over-year to $12.18 million in 2024, with net income rising to $3.25 million from $2.58 million in 2023.

• Earnings per share grew to $0.71 from $0.56, with weighted average shares unchanged at 4.59 million.

Financial highlights

• Operating income rose to $3.65 million from $2.86 million year-over-year.

• Total costs and expenses increased to $8.54 million from $8.02 million.

• Investment and other income totaled $461,668, up from $387,746.

• Net gain on marketable securities was $26,989 in 2024.

Outlook and guidance

• Anticipates Renacidin pharmaceutical sales to recover in 2025 as supply disruptions resolve.

• Expects continued demand for cosmetic ingredients and medical lubricants, especially in China.